Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

JARDIANCE under the microscope: Real-World safety check for korean kidney patients

NCT ID NCT06287073

Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study looked at the safety of the diabetes drug JARDIANCE (empagliflozin) in 299 Korean adults with chronic kidney disease. Researchers tracked side effects and measured changes in a key kidney health marker (urine albumin-creatinine ratio) after 12 and 24 weeks of treatment. The goal was to see how well the drug works and how safe it is in routine medical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Empagliflozin (JARDIANCE)
What this could lead to
If results are positive, this could confirm that JARDIANCE is safe and effective for Korean patients with chronic kidney disease in everyday practice.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

299 people

The number who actually took part.

Started

Mar 2024

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is a single-arm, open-label, multi-centre observational and non-interventional study (ONIS) based on newly collected data. This study will be carried out by enrolling patients in a consecutive manner into the study requiring completion of case report forms (CRFs) for all participants who initially administered JARDIANCE® following the study start date until the planned number of participants is reached.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≧19 years at enrolment * Patients diagnosed with CKD * Patients with CKD starting JARDIANCE® for the first time in accordance with the approved label in Korea * Patients who have provided informed consent and signed the data release consent form Exclusion Criteria: * Patients with previous exposure to JARDIANCE® * Patients with hypersensitivity to empagliflozin or to any of the excipients * Patients with type 1 diabetes * Patients with history of Diabetic Ketoacidosis (DKA) * Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption * Patients who are pregnant or are breastfeeding or who plan to become pregnant during the study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney disease, chronic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney disease, chronic

Contacts and locations

Locations

  • Chonnam National University Hospital

    Gwangju, 61469, South Korea

  • Chungbuk National University Hospital

    Cheongiu, 28644, South Korea

  • Hallym University Sacred Heart Hospital

    Anyang, 07441, South Korea

  • Inje University Ilsan Paik Hospital

    Goyang, 10380, South Korea

  • Korea University Anam Hospital

    Seoul, 02841, South Korea

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Soonchunhyang University Hospital Seoul

    Seoul, 04401, South Korea

  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital

    Seoul, 03312, South Korea

  • The Catholic University of Korea, Yeouido St.Mary's Hospital

    Seoul, 07345, South Korea

  • Ulsan University Hospital

    Ulsan, 44033, South Korea

  • Yonsei University Wonju Severance Christian Hospital

    Gangwon, 26426, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.